BOIRON : 2013 half-year activity

le
0

(Unaudited data)

. CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2013

In thousands of euros 2012 2013 Variation at current exchange rates Variation at constant exchange rates
France 145,398 159,597 +9.8% +9.8%
       
International : 96,120 116,187 +20.9% +21.8%
Incl. Europe (excluding France) 70,696 83,381 +17.9% +18.5%
Incl. North America 20,146 25,579 +27.0% +28.8%
Incl. Other countries 5,278 7,227 +36.9% +39.9%
Group Total 241,518 275,784 +14.2% +14.6%

In thousands of euros 2012 2013 Variation at current exchange rates Variation at constant exchange rates
Non-proprietary Homeopathic Medicines 143,633 152,097 +5.9% +6.0%
OTC Specialties 97,583 123,466 +26.5% +27.3%
Other 302 221 -26.8% -28.1%
Group Total 241,518 275,784 +14.2% +14.6%

. ACTIVITY IN THE QUARTER (variation at current rate)

In thousands of euros 1st Quarter 2nd Quarter
2012 2013 Var. 2012 2013 Var.
France 74,188 84,270 +13.6% 71,210 75,327 +5.8%
International : 54,904 73,751 +34.3% 41,216 42,436 +3.0%
Incl. Europe (excluding France) 41,807 54,334 +30.0% 28,889 29,047 +0.5%
Incl. North America 10,285 15,562 +51.3% 9,861 10,017 +1.6%
Incl. Other countries 2,812 3,855 +37.1% 2,466 3,372 +36.7%
Group Total 129,092 158,021 +22.4% 112,426 117,763 +4.7%

In thousands of euros 1st Quarter 2nd Quarter
2012 2013 Var. 2012 2013 Var.
Non-proprietary Homeopathic Medicines 73,427 79,062 +7.7% 70,206 73,035 +4.0%
OTC Specialties 55,576 78,866 +41.9% 42,007 44,600 +6.2%
Other 89 93 +4.5% 213 128 -39.9%
Group Total 129,092 158,021 +22.4% 112,426 117,763 +4.7%

2013 SECOND QUARTER HIGHLIGHTS

  • After a growth by 22.4% in the first quarter due notably to the strong pathology, sales revenue in the second quarter increased by 4.7% at current exchange rate (+5.2% at constant exchange rate).
  • Unda has announced its attention to reorganize its activities in order to ensure the development of homeopathy in Belgium. This project, likely to have social effects on the two Belgian sites, could affect around 60 employees over 194.
  • In the United States, the settlement agreement aimed to put an end to the legal proceeding relating to Children's Coldcalm® medicine in California obtained the prior approval of the Los Angeles court. Boiron USA is awaiting the court's final approval of the agreement. A provision of one million US dollars was recorded in the accounts as of December 31, 2011, which we still believe is corresponding to the risk incurred.
  • On June 30, 2013, the cash position of the group is exceeding 100 million euros against 94.7 million euros on December 31, 2012.

The half-year profitability should be in noticeable progress. In support of these performances, the group confirms targeting a new increase of its activity and profitability in 2013.

Our next update:
August 29, 2013: at market close, publication of 2013 half-year results.
Person responsible for financial information: Philippe MONTANT
Contact for financial information: Véronique BOUSCAYROL
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : finances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at: www.boiron.com

Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-32800-boi-120713-ca-t2-13-gb.pdf © Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant